Acasti Pharma announced that patient enrollment has been completed in the Company’s Phase 3 STRIVE-ON safety trial. The STRIVE-ON trial is a prospective, open-label, randomized, parallel group trial of GTX-104 compared with oral nimodipine, in 100 patients hospitalized for aSAH. Approximately 25 hospitals in the U.S. are participating.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACST:
- Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Acasti Pharma Appoints Prashant Kohli as CEO with Incentives
- Acasti Pharma sees cash runway into 2Q26
- Acasti Pharma reports Q1 EPS (24c) vs. (54c) last year
- Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update